There has been a growing trend of life science manufacturers collaborating with local governments (e.g., at the municipal and prefectural level) in Japan during the past 3-5 years. This trend is observed not only with domestic manufacturers but among foreign…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Japan Drug Makers Revving Up HR, Pay System Reforms; Eisai Mulling No Daily Allowance for Sales Reps
April 27, 2022
-
BUSINESS Sumitomo Scraps Daily Allowance for Sales Reps, Introduces Division Bonus to Boost Productivity
April 26, 2022
-
BUSINESS Chugai’s Q1 Sales Double on Ronapreve Bonanza, Brisk Hemlibra Export
April 26, 2022
-
REGULATORY Japan Panel OKs Comirnaty, Spikevax for 4th Shot, Use Limited to High-Risk People
April 26, 2022
-
REGULATORY SCARDA Provost Confident about Japanese Technologies, Wants to Mediate Company Matching
April 25, 2022
-
BUSINESS Biogen Pulls EU Application for Aduhelm
April 25, 2022
-
BUSINESS MSD Japan’s Sales Surge 7.5% in 2021, 1.5% Growth If Lagevrio Excluded: President
April 22, 2022
-
BUSINESS GSK Japan Chief Has High Hopes for Shingrix, Blenrep, RSV Jab as Future Growth Drivers
April 21, 2022
-
BUSINESS Lumakras, Bimzelx, Pivlaz Now Available in Japan
April 21, 2022
-
BUSINESS Post-Azilva, Takeda Set to Morph into Rare Disease Specialty Pharma in Japan
April 20, 2022
-
REGULATORY SCARDA Chief Sees First 5 Years as Critical, Japan-Made mRNA Jabs as Initial Work
April 19, 2022
-
REGULATORY Japan Approves Novavax’s COVID-19 Vaccine; Distribution to Start in Late May
April 19, 2022
-
REGULATORY Novavax COVID-19 Vaccine Clears MHLW Panel, Approval Expected Soon
April 19, 2022
-
COMMENTARY Ukraine War Sheds Light on Vulnerabilities in Pharmaceutical Supply Chains in Emergencies
April 19, 2022
-
REGULATORY Emergency Approval Plan Clears Lower House Panel; Opposition Bills Rejected, but Some Ideas Make It into Resolution
April 18, 2022
-
BUSINESS Bayer Yakuhin Sees 2021 Sales Skid 0.6% but Still Reach Target, Retains Spot in Top 10
April 15, 2022
-
BUSINESS Lumakras Nears Japan Market, Amgen Eyes Simultaneous Launch with US for Next 5 Oncology Drugs: EVP
April 14, 2022
-
REGULATORY Chuikyo OKs Listing of 8 Drugs on April 20; Vyvgart, Lumakras, and More
April 13, 2022
-
BUSINESS Shionogi’s COVID Pill Might Not Be Recommended for Pregnant Women over Birth Defect Risk
April 13, 2022
-
REGULATORY Vyvgart, Pivlaz to Be 1st to Face Zero Premium Rule for Low Cost Disclosures
April 12, 2022
ページ
Shionogi’s COVID-19 pill ensitrelvir failed to clear the second round of review by a key advisory panel on July 20. The session drew a great deal of attention since the drug is the first candidate for the application of Japan’s…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…